Company Filing History:
1 out of 212 
1 out of 832,880 Years Active: 1992-1994
Title: Zehra Kaymakcalan: Innovator in Peptide Medicaments
Introduction
Zehra Kaymakcalan is a prominent inventor based in El Cerrito, CA (US). She has made significant contributions to the field of medicinal peptides, focusing on treatments for diseases involving inflammatory responses. With a total of 2 patents, her work has the potential to impact various therapeutic areas.
Latest Patents
Kaymakcalan's latest patents include innovative peptide medicaments designed for the treatment of diseases. One patent details peptide medicaments and antibodies that are particularly effective in treating or preventing diseases characterized by inflammatory responses. These peptides are derived from the beta subunit, CD18, of leukocyte integrins. They possess properties that either interfere with or prevent undesirable leukocyte adhesion to biological materials, especially endothelial cells. This mechanism minimizes undesirable cell and tissue leukocyte binding, thereby preventing or reducing diseases that result from such interactions. Another patent focuses on a method for inhibiting the adhesion of white blood cells to endothelial cells. This patent describes proteins that can alter the adhesion between white blood cells and endothelial cells, ultimately preventing inflammatory-type diseases when administered in therapeutically effective amounts.
Career Highlights
Throughout her career, Kaymakcalan has worked with notable organizations, including Cetus Corporation. Her expertise in peptide medicaments has positioned her as a key figure in the development of innovative treatments for inflammatory diseases.
Collaborations
Zehra has collaborated with esteemed colleagues, including David Y Liu and L L Houston. These partnerships have further enhanced her research and development efforts in the field of medicinal peptides.
Conclusion
Zehra Kaymakcalan's contributions to the field of peptide medicaments highlight her innovative spirit and dedication to advancing medical science. Her patents reflect a commitment to addressing critical health challenges through targeted therapeutic solutions.